Expert Interview
Discussing the Phase 3 IMforte results for lurbinectedin + atezolizumab in extensive-stage small cell lung cancer
Ticker(s): PHM.MCPHMMFDr. Martin Wermke
Institution: TU Dresden
- Hematologist and oncologist directing the Early Clinical Trial Unit and Lung Cancer Program at Dresden’s National Center for Tumor Diseases, and chair of experimental tumor therapy.
- Principal investigator for over 200 Phase I trials, pioneering immunotherapies and advancing tarlatamab for neuroendocrine carcinomas.
- ESMO member and German Genomic Medicine Lung Cancer network steering committee participant, authoring numerous publications in leading journals.
Dr. Nicolas Girard
Institution: Institut Curie
- Full Professor and Pneumologist directing the Curie-Montsouris Thorax Institute and Medical Oncology Department at Institut Curie, specializing in thoracic oncology.
- Coordinator for over 50 clinical trials, advancing treatments for lung cancer and rare thymic tumors, notably through the RYTHMIC network and EURACAN.
- ESMO member and Versailles Saint Quentin University professor, authoring over 300 peer-reviewed publications in leading oncology journals.
PharmaMar is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. We are an integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer.
PharmaMar’s commitment to patients and to research has made it a world leader in the discovery of antitumor drugs of marine origin.
Please outline your current treatment first line treatment protocol for patients with SCLC.
Added By: joe_mccannIf the combination of lurbinectedin + atezolizumab for patients with extensive-stage small cell lung cancer becomes available at your institution, how would you use it?
If you would use it, on whom would you look to treat?
If this combination is available at your hospital what would it mean for use of durvalumab in 1st line induction? In the maintenance setting?
What is the significance of the IMforte data in terms of the holistic patient journey?
Does the data increase a patient's chance of receiving later line therapies eventually?
Given the safety profile seen in the IMforte results, how do you think about the tolerability of the combination in the typical patient?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
